Sorafenib tosylate - CAS 284461-73-0

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
APIs
Product Name
Sorafenib tosylate
Catalog Number
284461-73-0
CAS Number
284461-73-0
Molecular Weight
464.83
Molecular Formula
C21H16ClF3N4O3
COA
Inquire
MSDS
Inquire
Structure
CAS 284461-73-0 Sorafenib tosylate
Related Products
  • CAS 583840-03-3 Sorafenib-N-oxide

    Sorafenib-N-oxide
    (CAS: 583840-03-3)

    An impurity of Sorafenib. Sorafenib is a small inhibitor of several tyrosine protein kinases, such as VEGFR, PDGFR and Raf family kinases, for the treatment of ...

Reference Reading
1. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
Chetan Lathia, John Lettieri, Frank Cihon, Martha Gallentine, Martin Radtke, Pavur Sundaresan. Cancer Chemother Pharmacol (2006) 57: 685–692
On day 1 of period 1, all subjects received a single oral dose of sorafenib tosylate 50 mg tablet (calculated as free base sorafenib). After at least a 10-day washout, 400 mg ketoconazole (Nizoral, Janssen Pharmaceutica, Titusville, NJ; Batch 91P0982E) was administered for three consecutive days in period 2. On day 4 in period 2, a single dose of sorafenib tosylate 50 mg tablet (calculated as free base sorafenib) from the same batch as in period 1 was co-administered with 400 mg ketoconazole. Sorafenib doses were administered in the fasted state with 240 ml of water. Ketoconazole was administered for three additional days in period 2 (days 5, 6 and 7) to maintain CYP3A inhibition for the duration of blood sampling. Blood samples (5 ml) for the determination of sorafenib and its metabolite concentrations in plasma were collected before and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, and 168 h after drug administration. Samples were prepared by centrifugation to obtain plasma, which was frozen at -20 ℃ until analysis.
2005 - BOC Sciences | All rights reserved
DOWNLOAD